BIBF 1202

Cat. No.: HY-15992

CAS No.: 894783-71-2

Molecular Formula: $C_{30}H_{31}N_5O_4$

Molecular Weight: 525.6

Target: VEGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 45 mg/mL (85.62 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9026 mL	9.5129 mL	19.0259 mL
5 mM	0.3805 mL	1.9026 mL	3.8052 mL
10 mM	0.1903 mL	0.9513 mL	1.9026 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC_{50} of 62 nM.

IC_{50} & Target

IC50: 62 nM (VEGFR2)[1]

In Vitro

The major metabolic pathway for BIBF 1120 is methyl ester cleavage to BIBF 1202. Subsequently, the free carboxyl group of BIBF 1202 is glucuronidated to 1-O-acylglucuronide[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008 Jun 15;68(12):4774-82.

[2]. Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41(4):297-311.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA